Journal: Journal of pharmacological sciences
Article Title: A novel lysophosphatidic acid receptor 1 antagonist with high brain penetrability has a curative effect in the empathic pain-related fibromyalgia model.
doi: 10.1016/j.jphs.2025.03.012
Figure Lengend Snippet: Fig. 1. Chemical properties of Compound A (A) Structural information of Compound A (B) Dose-dependent inhibition of Compound A in LPA-induced 35S-GTPγS binding to the cell membrane. (C) Dose-dependent inhibition of Compound A in Ca2+ influx. (D) Specific binding evaluation of Compound A on GPCR in β-arrestin assay. LPA1, 2, 3, 5: lysophosphatidic acid receptor 1, 2, 3, 5, S1P1, 4: sphingosine-1-phosphate receptor 1, 4.
Article Snippet: BMS-986020, an LPA1 antagonist9 was purchased from MCE (Monmouth Junction, NJ, USA).
Techniques: Inhibition, Binding Assay, Membrane, Beta-Arrestin Assay